FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immunotherapy topics
Immunotherapy
Therapeutics
Antibodies
Immune Response
Monoclonal
Monoclonal Antibody
Stimulator
Immunostimulator
Compatibility
Histocompatibility
Specificity
Major Histocompatibility Complex
Radiation Therapy
Treatments
Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immunotherapy patents



      
           
This page is updated frequently with new Immunotherapy-related patent applications. Subscribe to the Immunotherapy RSS feed to automatically get the update: related Immunotherapy RSS feeds. RSS updates for this page: Immunotherapy RSS RSS


Date/App# patent app List of recent Immunotherapy-related patents
12/18/14
20140370099
 Artificial antigen presenting cells having a defined and dynamic shape patent thumbnailnew patent Artificial antigen presenting cells having a defined and dynamic shape
Compositions and methods comprising asymmetrical artificial antigen presenting cells (aapcs) are disclosed. The non-spherical aapcs more closely mimic endogenous cell-cell interactions and can be used for antigen-specific immunotherapy..
12/18/14
20140370086
 Sublingual immunotherapy with reduced oral itchiness patent thumbnailnew patent Sublingual immunotherapy with reduced oral itchiness
Sublingual immunotherapy (slit) with reduced oral itchiness is disclosed. The improved sublingual immunotherapy combines a monotonically increasing dose of allergen, along with a constant dose of mast cell stabilizer, thereby substantially avoiding the oral itchiness and other uncomfortable adverse reactions typically experienced with slit, which can improve patient compliance.
12/18/14
20140370039
 Il-12 immunotherapy for cancer patent thumbnailnew patent Il-12 immunotherapy for cancer
Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems.
12/18/14
20140369940
 Anti-alpha synuclein binding molecules patent thumbnailnew patent Anti-alpha synuclein binding molecules
Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific n-terminal and c-terminal epitopes on human α-synuclein.
12/11/14
20140363470
 Pharmaceutical formulations and the use thereof for the treatment of peanut allergy patent thumbnailPharmaceutical formulations and the use thereof for the treatment of peanut allergy
The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals, such as human mammals, suffering from peanut allergy. The present invention further relates to the use of the present compositions for the therapeutic treatment for desentizing the immune system of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment of a mammal with high predisposition to develop a certain allergy.
12/11/14
20140363446
 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics patent thumbnailPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
12/04/14
20140356930
 Immune system enhancing immunotherapy for the treatment of cancer patent thumbnailImmune system enhancing immunotherapy for the treatment of cancer
This application discloses immunoconjugates comprising antibodies against a particular target (such as cancer associated antigen or cancer specific antigen) that are conjugated with an immune enhancer, recruiter or solicitor. Also discloses are compositions and methods of using the inventive immunoconjugates to treat cancer..
12/04/14
20140356398
 Adoptive transfer of cd8+ t cell clones derived from central memory cells patent thumbnailAdoptive transfer of cd8+ t cell clones derived from central memory cells
The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic t lymphocytes (ctl) preparation in a treatment-effective amount. The method comprises administering as the ctl preparation a preparation consisting essentially of an in vitro expanded primate ctl population, the ctl population enriched prior to expansion for central memory t lymphocytes, and depleted prior to expansion of effector memory t lymphocytes.
12/04/14
20140356372
 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor patent thumbnailMethods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (sit) regimen.
11/27/14
20140349402
 Car+ t cells genetically modified to eliminate expression of t-cell receptor and/or hla patent thumbnailCar+ t cells genetically modified to eliminate expression of t-cell receptor and/or hla
The present invention concerns methods and compositions for immunotherapy employing a modified t cell comprising disrupted t cell receptor and/or hla and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf treatment of medical conditions such as cancer, autoimmunity, and infection.
11/27/14
20140348902
Tcl1 peptides for immunotherapy
Provided are tcl1 peptides that bind to mhc i (hla-a2) on tumor cells or other antigen-presenting cells and are recognized by t-cell receptors on t cells. The tcl1 peptides may be therapeutically used to treat a cancer, such as a b cell malignancy, leukemia, or lymphoma.
11/27/14
20140348846
Anti-hla class-ib antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (ivig) useful as therapeutic ivig mimetics and methods of their use
Provided herein are compositions comprising anti-hla-ib antibodies (monoclonal, mixed monoclonal, recombinant, chimeric, humanized or human antibodies) as ivig mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-hla-ib antibodies strongly mimic ivig in immunoreactivity to hla class ia (hla-a, hla-b and hla-cw) and ib antigens (hla-e, hla-f and hla-g).
11/27/14
20140348843
Apoe immunotherapy
The present invention provides antibodies that preferentially bind to an apoe(1-272) fragment relative to apoe(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases..
11/27/14
20140348783
Vaccine immunotherapy for immune suppressed patients
A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive t-cells and restoring t-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive t-cells and exposing the naive t-cells to endogenous or exogenous antigens at an appropriate site.
11/27/14
20140348782
Vaccine immunotherapy for immune suppressed patients
A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive t-cells and restoring t-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive t-cells and exposing the naive t-cells to endogenous or exogenous antigens at an appropriate site.
11/27/14
20140348743
Monoclonal antibodies to programmed death 1 (pd-1)
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
11/20/14
20140341982
Vaccination with immuno-isolated cells producing an immunomodulator
The present invention relates to immuno-protected encapsulated cells producing an immunomodulator, for example gm-csf (granulocyte-macrophage colony stimulating factor). The cells of the invention are particularly well adapted for providing an active adjuvant or immunomodulator, for example in the context of immunisation in humans and animals.
11/20/14
20140341978
Cancer immunotherapy
We formulated multiple tlr agonists into gvax (lethally irradiated tumor cell vaccines engineered to secrete gm-csf). Specifically, gla and r848, tlr4 and tlr7/8 agonists found to be safe in patients, were formulated with gvax (tegvax—for tlr agonists enhanced gvax), and this formulation was effective in producing anti-tumor responses in 3 different preclinical models, including palpable b16.
11/20/14
20140341931
Soluble cd27 (scd27) and the use thereof
Disclosed are methods of diagnosing a subject as having a solid tumor or a predisposition to developing a solid tumor. The methods include detecting or quantitating the amount of scd27 in a serum sample obtained from a subject and comparing that amount of scd27 with a control value indicative of the basal level of scd27 present in the serum of a subject that does not have a solid tumor or a predisposition to developing a solid tumor, wherein a reduction of the amount of scd27 relative to the control value indicates that the subject has the solid tumor or the predisposition to developing the solid tumor.
11/13/14
20140335549
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy.
11/06/14
20140328833
Methods for treating cancer using anti-pd-1 antibodies
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
10/30/14
20140322253
Cyclin a1-targeted t-cell immunotherapy for cancer
Compositions and methods are provided for eliciting antigen-specific t-cell responses against human cyclin a1 (ccna1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (aml) including leukemia stem cells (lsc) and in immunologically privileged testis cells, but not in other normal cell types. Ccna1-derived peptide epitopes that are immunogenic for t-cells including ctl are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells..
10/30/14
20140322183
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
The present invention provides compositions and methods for regulating the specificity and activity of t cells. In one embodiment, the invention provides a type of chimeric antigen receptor (car) wherein the car is termed a “kir-car” which is a car design comprising a component of a receptor naturally found on natural killer (nk) cells.
10/23/14
20140314795
Method and compositions for cellular immunotherapy
The present invention provides methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring genetically modified tumor specific cd8+ t cells in the presence of tumor-specific, subset specific genetically modified cd4+ t cells, wherein the cd4+ t cells confer and/or augment a cd8+ t cells ability to sustain anti-tumor reactivity and increase and/or maximize tumor-specific proliferation of the tumor-specific cd8+ t cells of interest. Pharmaceutical formulations produced by the method, and methods of using the same, are also described..
10/16/14
20140308344
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
10/16/14
20140308305
Yeast-based vaccines as immunotherapy
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed..
10/16/14
20140308299
Combination immunotherapy for the treatment of cancer
Agonists to icos in combination with a blocking agent to a t cell inhibitory receptor (e.g., ctla-4, pd-1, etc.) are demonstrated herein to be useful for the treatment of tumors.. .
10/09/14
20140302098
Yeast-based vaccines as immunotherapy
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed..
10/09/14
20140301945
Human anti-sod1 antibodies
Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or sod1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for sod1 are also disclosed.
10/02/14
20140296480
Peptide secreted by lactobacillus plantarum with immunomodulating function
To summarize, the st peptide is considered to promote the process of immunologic ignorance of our gastrointestinal immune system toward the commensal bacteria of our gastrointestinal tract, thus favoring the mechanisms of oral tolerance. Therefore the st peptide could be used in immunotherapy, especially in the context of certain autoimmune diseases and certain inflammatory diseases..
10/02/14
20140294852
Monoclonal antibodies to programmed death 1 (pd-1)
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
10/02/14
20140294765
Lsr antibodies, and uses thereof for treatment of cancer
This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for lsr molecules, which are suitable drugs for immunotherapy and treatment of specific cancer.. .
09/25/14
20140286974
Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the pfr1 protein of leishmania infantum with specific immunodominant epitopes
The present invention claims an isolated nucleotide sequence characterized by encoding the pfr1 protein of leishmania infantum or a fragment thereof. This pfr1 protein or a fragment thereof comprises at least a selected immunodominant epitope between the following group: seq id no: 1, seq id no: 2, seq id no: 3, seq id no: 4, seq id no: 5, seq id no: 6, seq id no: 7 and seq id no: 8, where the immunodominant epitope is able to induce an antigen-specific t cell cytotoxic immune response in an animal, against the kinetoplastids causing the leishmaniasis disease.
09/25/14
20140286963
Methods and compositions for neural disease immunotherapy
The invention provides antibodies to specific neural proteins and methods of using the same.. .
09/18/14
20140275495
Humanized antibodies that recognize alpha-synuclein
The present application discloses humanized 9e4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of lewy body disease..
09/18/14
20140271836
Manufacture of peanut formulations for oral desensitization
The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies..
09/18/14
20140271721
Peanut formulations and uses thereof
The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy..
09/18/14
20140271692
Novel immunogenic epitopes for immunotherapy
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
09/18/14
20140271690
Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type
The present disclosure is directed to individual aβ peptide immunogen constructs, peptide compositions comprising these aβ peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these aβ peptide immunogen constructs, with the individual aβ peptide immunogen constructs having the n-terminus of the aβ peptide as the b cell (b) epitopes linked through spacer residue(s) to heterologous t helper cell (th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the n-terminus of the aβ peptide offering protective immune responses to patients at risk for, or with, alzheimer's disease.. .
09/18/14
20140271638
Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide.
09/18/14
20140271582
Cd123-specific chimeric antigen receptor redirected t cells and methods of their use
A family of chimeric antigen receptors (cars) containing a cd123 specific scfv was developed to target different epitopes on cd123. In some embodiments, such a cd123 chimeric antigen receptor (cd123car) gene includes an anti-cd123 scfv region fused in frame to a modified igg4 hinge region comprising an s228p substitution, an l235e substitution, and optionally an n297q substitution; a costimulatory signaling domain; and a t cell receptor (tcr) zeta chain signaling domain.
09/18/14
20140271477
Monoclonal antibodies to egfr, and uses therefor
The present invention relates to isolated monoclonal anti-egfr antibodies, and to the use of such antibodies and antibody fragments to detect egfr, particularly those expressed by cancer cells. The antibodies are useful in diagnostic as well as therapeutic indications.
09/11/14
20140256648
Hjurp peptides and vaccines including the same
Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic t cell inducibility of the original sequence.
09/11/14
20140255437
Topk peptides and vaccines including the same
The present invention provides isolated epitope peptides derived from topk and immunogenic fragments thereof have an ability to induce cytotoxic t lymphocytes (ctls) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a topk-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have ctl inducibility.
09/11/14
20140255434
Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity
The present invention relates to the preparation and use of variants of the group 5 allergen of the pooideae which are characterised by reduced ige reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with t lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies..
09/11/14
20140255433
Pde5 inhibitor compositions and methods for immunotherapy
The invention features methods and compositions featuring a pde5 inhibitor for treating or preventing immunological-mediated disease in a subject.. .
09/11/14
20140255411
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
09/11/14
20140255389
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
09/11/14
20140255304
Tdp-43 specific binding molecules
Provided are novel tdp-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these tdp-43 specific binding molecules.
09/04/14
20140248640
Methods for testing an immune response using cultures of t cells, b cells, dendritic cells and follicular dendritic cells
The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising t cells, b cells and antigen-primed dendritic cells.
09/04/14
20140248297
Predictors of response to immunotherapy
The invention is directed to a method to predict individuals who are likely to respond to immunotherapy by detecting enhanced levels of antibodies in the plasma or serum wherein the antibodies are characteristic of the response or non-response of pretested populations of subjects.. .
09/04/14
20140248283
Monoclonal antibodies against her2 antigens, and uses therefor
The present invention provides and includes monoclonal antibodies (mabs) preferentially selective for her2 antigens, hybridoma lines that secrete these her2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect her2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of her2.
08/28/14
20140242101
Pd-l1 based immunotherapy
The present invention relates to the field of prophylaxis and therapy of clinical conditions including cancer, autoimmune diseases and infectious diseases. In particular there is provided vaccine compositions comprising pd-l1 or peptide fragments thereof that are capable of eliciting immune responses useful in treatment of cancer, autoimmune diseases or infectious diseases..
08/28/14
20140242049
Mutant ctla4 gene transfected t cell and composition including same for anticancer immunotherapy
A transformed t-cell for t-cell therapy, and a composition including the same for anticancer immunotherapy. More particularly, the transformed t-cell is characterized by the transfection of a gene for coding a chimera protein.
08/21/14
20140234347
Methods of using biomarkers for predicting the outcome of an immunotherapy against cancer
The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers.
08/07/14
20140220605
Vmp-like sequences of pathogenic borrelia species and strains
The present invention relates to dna sequences encoding vmp-like polypeptides of pathogenic borrelia, the use of the dna sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the dna and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, dna segments and antibodies..
08/07/14
20140220562
Method of predicting responsiveness of b cell lineage malignancies to active immunotherapy
Predictive biomarkers identify those patients suffering from immunoglobulin positive (ig+) b lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the cdr1 (herein termed cdr1-y10) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of cdr1 tyrosine residues (herein termed cdr1-yhi) is predictive of a low anti tumor response..
08/07/14
20140220011
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, clorf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
08/07/14
20140219914
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
07/31/14
20140212422
Methods for treating cancer using anti-pd-1 antibodies in combination with anti-ctla-4 antibodies
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
07/24/14
20140206724
Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
07/24/14
20140206723
Methods for treating amyloidosis with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
07/24/14
20140206654
Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
The present invention refers to the use of a compound of formula (i′) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodysplastic syndromes (mdss) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (i″) for the treatment and/or prophylaxis of cancer of an organ..


Popular terms: [SEARCH]

Immunotherapy topics: Immunotherapy, Therapeutics, Antibodies, Immune Response, Monoclonal, Monoclonal Antibody, Stimulator, Immunostimulator, Compatibility, Histocompatibility, Specificity, Major Histocompatibility Complex, Radiation Therapy, Treatments, Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



0.3006

3518

1 - 1 - 71